

ja 1624

PATENT Attorney Docket No. UDL-003C1

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Darrow et al.

**CONFIRMATION NO.:** 

8430

**SERIAL NO.:** 

10/083,245

**GROUP NO.:** 

1624

FILING DATE:

February 25, 2002

**EXAMINER:** 

Not yet assigned

TITLE:

CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO

[1,5-a]-1,3,5-TRIAZINES

# CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this and day of July, 2004.

Lica Marie Solis

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

#### Submitted herewith are:

- 1. Transmittal Form (1 page);
- 2. Supplemental Information Disclosure Statement (3 pages); and
- 3. Form PTO-1449 (1 page);
- 4. Copy of cited references A1-A7 and B1-B5; and
- 5. A Return Receipt Postcard.

3089132-1

	567										
i			Application	Serial Number		10/083,245					
) JUL	0 7 2004 C		Filing Date			February 25, 2002					
			First Name	rst Named Inventor		Darrow					
NSMITTAL			Group Art V	p Art Unit		1624					
			Examiner N	xaminer Name		Not yet assigned					
FORM			Attorney Docket No.		İ	UDL-003C1					
			Patent No.	<u> </u>		Not yet assigned					
			Issue Date	e Date		Not yet assigned					
	ENCLOSURES (check all that apply)										
☐ Fee	e Transmittal Form	<b>;</b>	Copy of Notic Parts of Appli	e to File Missing cation		Notice of Appeal to Board of Patent Appeals and Interferences					
	☐ Check Attached☐ Copy of Fee Transmittal Form		Formal Drawi								
	Amendment/Response		Request For C Examination ( Transmittal			] Status Inquiry					
	After Final					Return Receipt Postcard					
	Affidavits/declaration(s) Letter to Official Draftsperson			Power of Attorney Revocation of Prior Powers)		Certificate of First Class Mailing under 37 C.F.R. 1.8					
	including Drawings [Total Sheets]		Terminal Disc	laimer		Certificate of Facsimile Transmission under 37 C.F.R. 1.8					
	Petition for Extension of Time			laration and Power r Utility or Design ation		Additional Enclosure(s) (please identify below)					
⊠	Supplemental Information Disclosure Statement		Small Entity S	tatement							
	<ul><li>✓ Form PTO-1449</li><li>✓ Copies of IDS</li><li>Citations A1-A7 and</li><li>B1-B5</li></ul>		CD(s) for larg	CD(s) for large table or computer program							
	Certified Copy of Priority Document(s)		Amendment A	After Allowance							
	Sequence Listing submission Paper Copy/CD Computer Readable Copy Statement verifying identity of above		Request for Correction  Correction  Certificate duplicate)	ertificate of e of Correction (in							
CORRESPONDENCE ADDRESS				SIGNATURE BL	OCI						
Direct all correspondence to:  Patent Administrates, Hurwitz & High Street Tow 125 High Street Boston, MA 02: Tel. No.: (617) 2 Fax No.: (617) 2			Date: July <b>Z</b> , 2004 Reg. No. 45,508 Tel. No.: (617) 248-		-722						



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Darrow et al.

CONFIRMATION NO.:

8430

**SERIAL NO:** 

10/083,245

**GROUP NO.:** 

1624

FILING DATE:

February 25, 2002

**EXAMINER:** 

Not yet assigned

TITLE:

CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO

[1,5-a]-1,3,5-TRIAZINES

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

In addition, Applicants wish to inform the Examiner about the following patents and patent applications, and the contents of their file wrappers, including all Office actions issued therein.

- 1) U.S.S.N. 09/676,970, entitled "Certain Alkylene Diamine-Substituted Pyrazolo [1,5-a]-1,3,5-Triazines," filed on September 29, 2000, and issued on April 16, 2002, as U.S. Patent No. 6,372,743 B1 (Reference A1).
- 2) U.S.S.N. 09/676,941, entitled "Certain Alkylene Diamine-Substituted Heterocycles," filed on September 29, 2000, and issued on January 14, 2003, as U.S. Patent No. 6,506,762 B1 (Reference A2).
- 3) U.S.S.N. 10/291,446, entitled "Certain Alkylene Diamine-Substituted Heterocycles," filed on November 8, 2002, and issued on February 24, 2004, as U.S. Patent No. 6,696,445 B2 (Reference A4).
- 4) U.S.S.N. 10/705,446, entitled "Certain Alkylene Diamine-Substituted Heterocycles," filed on November 10, 2003.

- 5) U.S.S.N. 10/274,851, entitled "Substituted 2-Cyclohexyl-4-Phenyl-1H-Imidazole Derivatives," filed on October 21, 2002, and published on July 31, 2003, as U.S. Application Publication No. 2003/0144290 (Reference A6).
- 6) U.S.S.N. 10/415,457, entitled "Spiro[Isobenzofuran-1,4'-Piperidin]-3-Ones and 3H-Spiroisobenzofuran-1,4'-Piperidines," filed on April 29, 2003.
- 7) U.S.S.N. 09/771,956, entitled "Chimeric Neuropeptide Y Receptors," filed on January 29, 2001, and published on October 18, 2001, as U.S. Application Publication No. 2001/0031474 (Reference A5).
- 8) U.S.S.N. 10/013,846, entitled "Spiro[Isobenzofuran-1,4'-Piperidin]-3-Ones and 3H-Spiroisobenzofuran-1,4'-Piperidines," filed on December 11, 2001, and issued on May 20, 2003, as U.S. Patent No. 6,566,367 B2 (Reference A3).
- 9) U.S.S.N. 10/410,648, entitled "Spiro[Isobenzofuran-1,4'-Piperidin]-3-Ones and 3H-Spiroisobenzofuran-1,4'-Piperidines," filed on April 9, 2003, and published on April 15, 2004, as U.S. Application Publication No. 2004/0072847 (Reference A7).

#### **REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

(1)	within three (3) months of the <b>filing date</b> of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the <b>date of entry of the national stage</b> as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the <b>first Office action</b> on the merits, or before the mailing of a <b>first Office action</b> after the filing of a request for continued examination under 37 C.F.R. 1.114; or
(2)	after the period defined in (1) but before the mailing date of a <b>final action</b> or a <b>notice of allowance</b> under 37 C.F.R. 1.311, and
	the requisite Statement is below, OR
	the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or
(3)	after the mailing date of a final action or notice of allowance but before the payment of the issue fee, AND
	the requisite Statement is below AND

Supplemental Information Disclosure Statement Serial No. 10/083,245 Page 3 of 3

the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

#### **STATEMENT**

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- 1. Each item of information contained in the Information Disclosure

  Statement was first cited in any communication from a foreign patent

  office in a counterpart foreign application **not more than three months**prior to the filing of the Information Disclosure Statement; or
- No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Date: July 2, 2004 Reg. No. 45,508

П

Tel. No.: (617) 248-7226 Fax No.: (617) 248-7100

3081840

Respectfully submitted,

Daniel A. Wilson

Attorney for the Applicants Testa, Hurwitz & Thibeault, LLP

High Street Tower 125 High Street

Boston, Massachusetts 02110



FORM PTO - 1449  ATTORNEY DOCKET NO.: UDL-003C1  SUPPLEMENTAL INFORMATION  APPLICANT(S): Darrow et al.						
DISCLOSURE STATEMENT	APPLICANT(S): Darrow et al.  SERIAL NO.: 10/083,245					
FILING DATE: February 25, 2002 GROUP	: 1624					
U.S. PATENT DOCUMENTS						
	FILING DATE IF APPROPRIATE					
A1 6,372,743 B1 04/16/2002 Darrow et al. 09/2	9/2000					
A2 6,506,762 B1 01/14/2003 Horvath et al. 09/2	9/2000					
A3 6,566,367 B2 05/20/2003 Bakthavatchalam et al. 12/1	12/11/2001 11/08/2002 01/29/2001					
A4 6,696,445 B2 02/24/2004 Horvath et al. 11/0						
A5 2001/0031474 A1 10/18/2001 Kinrade et al 01/2						
A6 2003/0144290 A1 07/31/2003 Blum et al. 10/2	1/2002					
A7 2004/0072847 A1 04/15/2004 Bakthavatchalam et al. 04/0	9/2003					
FOREIGN PATENT DOCUMENTS						
EXAM. DOCUMENT DATE COUNTRY CLASS SUB FILING ABSTRACT CODE CLASS DATE ONLY	ENGLISH LANG (Y/N)					
B1 WO 01/23387 04/05/2001 PCT N	Y					
B2 WO 01/23389 04/05/2001 PCT N	Y					
B3 WO 01/55103 08/02/2001 PCT N	Y					
B4 WO 02/48152 06/20/2002 PCT N	Y					
B5 WO 03/104255 12/18/2003 PCT N	Y					
OTHER ART, JOURNAL ARTICLES, ETC.						
EXAM. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) INIT.						

DATE CONSIDERED

**EXAMINER**